---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-009744"
form_type: "8-K"
ticker: "HEPA"
cik: "0001583771"
company_name: "Hepion Pharmaceuticals, Inc."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-21T23:38:02.936458+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Hepion delisted from Nasdaq; pivots to diagnostics via New Day license

## Summary
- Received Nasdaq delisting notice for failing to maintain $1.00 bid price and being deemed a public shell; trading suspended May 13, 2025.
- Expects common stock to trade on OTC Markets under symbol HEPA after suspension.
- Entered license agreement with New Day Diagnostics on May 9, 2025, for diagnostic tests (celiac, respiratory multiplex, H. pylori, HCC).
- Celiac, respiratory, and H. pylori tests have CE marks and are eligible for sale in Europe.

## SEC filing metadata
- accession: 0001641172-25-009744
- form_type: 8-K
- ticker: HEPA
- cik: 0001583771
- company_name: Hepion Pharmaceuticals, Inc.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583771/000164117225009744/0001641172-25-009744-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583771/000164117225009744/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-009744
- JSON: https://secwatch.observer/filing/0001641172-25-009744.json
- Plain text: https://secwatch.observer/filing/0001641172-25-009744.txt

## Key facts
- Listing & Compliance Notices
  Hepion Pharmaceuticals, Inc. received a nasdaq delisting notice notice regarding other (rules 5550(a)(2), 5101).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Rules: 5550(a)(2), 5101
  source text: May 9, 2025, Hepion Pharmaceuticals, Inc. (the “Company) received written notice (the “Notice”) from the Office of General Counsel of The Nasdaq Stock Market (“Nasdaq”) indicating that the Nasdaq Hearings Panel has determined to delist the Company’s shares from Nasdaq due to the Company’s failure to meet Nasdaq’s continued listing standards. As previously disclosed, the Company has not been compliant with the requirements under Nasdaq Listing Rule 5550(a)(2) to maintain a minimum bid price of $1.00 per share and Nasdaq Listing Rule 5101 indicating that Nasdaq believes the Company is a public s
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583771/000164117225009744/0001641172-25-009744-index.htm
- Listing & Compliance Notices
  Hepion Pharmaceuticals, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5101).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5101
  source text: May 9, 2025, Hepion Pharmaceuticals, Inc. (the “Company) received written notice (the “Notice”) from the Office of General Counsel of The Nasdaq Stock Market (“Nasdaq”) indicating that the Nasdaq Hearings Panel has determined to delist the Company’s shares from Nasdaq due to the Company’s failure to meet Nasdaq’s continued listing standards. As previously disclosed, the Company has not been compliant with the requirements under Nasdaq Listing Rule 5550(a)(2) to maintain a minimum bid price of $1.00 per share and Nasdaq Listing Rule 5101 indicating that Nasdaq believes the Company is a public s
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583771/000164117225009744/0001641172-25-009744-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.